Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06423703 · ClinicalTrials.gov registry record · Phase 3
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
A Phase 3 study of Acute Pain, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 10
- Study locations
NCT06423703: Completed Phase 3 study of Acute Pain, sponsored by Tris Pharma.
NCT06423703 is a Phase 3 study of Acute Pain that has completed, run by Tris Pharma. The registered enrollment target is 240 participants, roughly in line with the 263-participant average among 50 other Acute Pain trials with a reported enrollment target. The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06423703, a Phase 3 study of Acute Pain, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cebranopadol
- DRUG Oxycodone IR
- DRUG Placebo Only
Study Locations (10)
Texas
- Alleviate 2 001113 - Houston
- ALLEVIATE 2 Site 001104 - McAllen
- ALLEVIATE 2 Site 001111 - San Antonio
Alabama
- ALLEVIATE 2 Site 001108 - Sheffield
Arkansas
- ALLEVIATE 2 Site 001106 - Little Rock
Florida
- ALLEVIATE 2 Site 001103 - Tampa
Georgia
- ALLEVIATE 2 Site 001102 - Atlanta
Kansas
- ALLEVIATE 2 Site 001107 - Overland Park
Maryland
- ALLEVIATE 2 Site 001105 - Pasadena
Utah
- ALLEVIATE 2 Site 001101 - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 3 |
What the finished NCT06423703 record still lists
NCT06423703 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 263-participant average among 50 other Acute Pain trials with a reported enrollment target.
The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06423703 lists 10 locations in 8 states (Texas, Alabama, Arkansas).
Frequently Asked Questions
What is clinical trial NCT06423703 about?
NCT06423703 is a clinical study titled "A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy". The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
What is the current status of trial NCT06423703?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2024-07-18. Estimated completion is 2025-01-31.
What conditions does trial NCT06423703 study?
This clinical trial studies the following conditions: Acute Pain.
What interventions are being tested in trial NCT06423703?
The interventions under investigation include: Placebo (DRUG), Cebranopadol (DRUG), Oxycodone IR (DRUG), Placebo Only (DRUG).
Who is sponsoring clinical trial NCT06423703?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06423703 being conducted?
This trial has 10 study locations across Alabama, Arkansas, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06423703's enrollment target sits among peer trials
240 13th of 50 higher than 38 of 50 other Acute Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of XP20B Following Bunionectomy Surgery
COMPLETED · Phase 3
-
Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department
COMPLETED · Phase 3
-
Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion
COMPLETED · Phase 3
-
Erector Spinae Block Versus Surgeon Infiltration in VATS Procedures
COMPLETED · Phase 3
-
Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone
COMPLETED · Phase 3
-
Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI